The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis
Maria Schubert(University of Münster), Martin Spahn(Universitätsklinikum Würzburg), Markus Graefen(Eppendorf (Germany)), Bertrand Tombal(Cliniques Universitaires Saint-Luc), Jochen Walz(Institut Paoli-Calmettes), G. Marchioro(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paolo Gontero(Fondazione Ricerca Molinette), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Susanne Kneitz(University of Würzburg), Burkhard Kneitz(Universitätsklinikum Würzburg), R. Jeffrey Karnes(Mayo Clinic), Claus Jürgen Scholz(University of Würzburg), D. Frohneberg(Städtisches Klinikum Karlsruhe), Chris Bangma(Erasmus MC), Fritz H. Schröder(Meertens Institute), Paul Van Cangh, Pia Bader(Städtisches Klinikum Karlsruhe), Chao‐Yu Hsu(National Chung Hsing University), Steven Joniau
Cited by 9
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)
|The Lancet|2005|1.1k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
MicroRNAs in the Human Heart
|Circulation|2007|888